CEO of Shield Therapeutics (STX) Carl Sterritt stopped by our studio to give us an insight into the FDA's approval of their lead asset Ferracru, detailing what this means for commercialisation and the future of the drug. In addition, Carl discussed why this win is good for the healthcare sector as a whole and clues us in to what to expect from STX next.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
